ATRS - Antares Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Total Revenue
123,864
123,864
63,554
54,515
52,222
Cost of Revenue
50,475
50,475
31,065
27,466
28,817
Gross Profit
73,389
73,389
32,489
27,049
23,405
Operating Expense
72,397
72,397
49,090
43,500
47,522
Operating Income
992
992
-16,601
-16,451
-24,116
Net Non Operating Interest Income Expense
-3,549
-3,549
-2,675
-1,423
79.783
Other Income Expense
530
530
12,761
1,131
-202.127
Pretax Income
-2,027
-2,027
-6,515
-16,743
-24,239
Tax Provision
0
0
0
0
100
Net Income Common Stockholders
-2,027
-2,027
-6,515
-16,743
-24,339
Diluted NI Available to Com Stockholders
-2,027
-2,027
-6,515
-16,743
-24,339
Basic EPS
-
0
0
0
0
Diluted EPS
-
0
0
0
0
Basic Average Shares
-
202,700
162,875
156,054
154,992
Diluted Average Shares
-
202,700
162,875
156,054
154,992
Total Operating Income as Reported
992
992
-4,101
-16,451
-24,116
Total Expenses
122,872
122,872
80,155
70,966
76,339
Net Income from Continuing & Discontinued Operation
-2,027
-2,027
-6,515
-16,743
-24,339
Normalized Income
-2,027
-2,027
-19,015
-17,603
-24,337
Interest Income
-
-
-
-
79.783
Interest Expense
3,549
3,549
2,675
1,423
-
Net Interest Income
-3,549
-3,549
-2,675
-1,423
79.783
EBIT
1,522
1,522
-3,840
-15,320
-24,116
EBITDA
4,079
-
-
-
-
Reconciled Cost of Revenue
50,475
50,475
31,065
27,466
28,817
Reconciled Depreciation
2,557
2,557
2,724
2,104
1,861
Net Income from Continuing Operation Net Minority Interest
-2,027
-2,027
-6,515
-16,743
-24,339
Total Unusual Items Excluding Goodwill
0
0
12,500
860
-2.691
Total Unusual Items
0
0
12,500
860
-2.691
Normalized EBITDA
4,079
4,079
-13,616
-14,076
-22,253
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
-1.0764